Mankind Pharma Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Share holding
• Capital structures
• Ratio

Mar ' 25	Mar ' 24	Mar ' 23	Mar ' 22	Mar ' 21

Sources of funds

Owner's fund

Equity share capital

41.26

40.06

40.06

40.06

40.06

Share application money

-

23.25

-

-

-

Preference share capital

-

-

-

-

-

Reserves & surplus

14,599.01

9,560.50

7,743.85

6,028.72

4,694.21

Loan funds

Secured loans

7,248.25

-

-

687.89

95.00

Unsecured loans

-

-

-

-

-

Total

21,888.52

9,623.81

7,783.91

6,756.67

4,829.27

Uses of funds

Fixed assets

Gross block

4,277.38

3,953.49

3,551.71

3,185.08

1,193.84

Less : revaluation reserve

-

-

-

-

-

Less : accumulated depreciation

806.63

549.15

409.49

298.56

206.43

Net block

3,470.75

3,404.34

3,142.22

2,886.52

987.41

Capital work-in-progress

207.43

187.58

494.78

386.57

165.57

Investments

16,683.38

4,430.13

3,102.23

2,148.44

2,396.89

Net current assets

Current assets, loans & advances

3,466.76

3,395.66

2,631.89

2,991.33

2,330.46

Less : current liabilities & provisions

1,939.80

1,793.90

1,587.21

1,656.18

1,051.06

Total net current assets

1,526.96

1,601.76

1,044.68

1,335.15

1,279.40

Miscellaneous expenses not written

-

-

-

-

-

Total

21,888.52

9,623.81

7,783.91

6,756.67

4,829.27

Notes:

Book value of unquoted investments

15,124.52

2,190.62

2,040.76

1,760.67

2,396.89

Market value of quoted investments

1,558.86

2,239.51

1,061.47

387.77

-

Contingent liabilities

4,261.71

449.91

168.37

275.47

-

Number of equity sharesoutstanding (Lacs)

4125.79

4005.88

4005.88

4005.88

4005.88